ARTL Projected Dividend Yield

Com Par $0.001/Artelo Biosciences Inc ( NASDAQ : ARTL )

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer.

20 YEAR PERFORMANCE RESULTS